Obi Pharma, Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for DNA alkylating agents (US 10,364,261) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 2 fees due Mar 10 to 12, 2027 · next Mar 10
- 1 fee due Apr 3, 2027The maintenance fee for Methods of Making High Enantioselective Secondary Alcohols (US 11,773,118) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 3 fees due Jun 5 to 30, 2027 · next Jun 5
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,517,936 | Vaccines with Higher Carbohydrate Antigen Density and Novel Saponin Adjuvant In force · High confidence | In force | High confidence | |
| US 11,752,204 | Vaccines with Higher Carbohydrate Antigen Density and Novel Saponin Adjuvant In force · High confidence | In force | High confidence | |
| US 12,053,514 | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment In force · USPTO record | In force | USPTO record | |
| US 10,815,307 | Antibodies, Pharmaceutical Compositions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,364,261 | DNA alkylating agents In force · USPTO record | In force | USPTO record | |
| US 10,766,914 | DNA alkylating agents In force · USPTO record | In force | USPTO record | |
| US 10,829,437 | Nitrobenzyl derivatives of anti-cancer agents In force · USPTO record | In force | USPTO record | |
| US 11,535,585 | Nitrobenzyl derivatives of anti-cancer agents In force · USPTO record | In force | USPTO record | |
| US 10,409,869 | (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation In force · USPTO record | In force | USPTO record | |
| US 10,501,532 | Novel Carbohydrate Antibodies, Pharmaceutical Compositions and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 3 patents in force now held by others · 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 2 abandoned · 8 no status recorded
Showing 1 to 10 of 15, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/253,986 | Bispecific Dendritic Cell Engager and Uses Thereof | Jun 30, 2025 | Pending |
| 18/862,675 | Synthesis Methods of Acyl Chain of QS-21 and Derivative Thereof | May 5, 2023 | Pending |
| 18/685,917 | Bispecific Dendritic Cell Engager and Uses Thereof | Aug 30, 2022 | Pending |
| 18/264,563 | Novel Carbohydrate Antibodies, Pharmaceutical Compositions and Uses Thereof | Feb 9, 2022 | Abandoned |
| 18/259,277 | Feb 9, 2022 | No status recorded | |
| 18/253,576 | Active Cancer Immunotherapy by Immune Modulation via Globo Series Antigens | Nov 19, 2021 | Abandoned |
| 18/288,215 | Combination Therapy by Using AKR1C3-ACTIVATED Compound with Immune Checkpoint Inhibitor | Apr 28, 2021 | Pending |
| 18/261,137 | Use of AKR1C3-ACTIVATED Compound | Feb 26, 2021 | Pending |
| 17/789,796 | Dec 30, 2020 | No status recorded | |
| 17/006,881 | Aug 30, 2020 | No status recorded |
10 of 15 applications shown.
Pro members see all 15 published applications.